Safety and efficacy of ruxolitinib (RUX) in patients with myelofibrosis (MF) who started treatment at 10mg BID and HAD the dose uptitrated in the phase 3b expanded-access jump study

Authors
Category Primary study
JournalHaematologica
Year 2017
This article has no abstract
Epistemonikos ID: e9e967da23c1d4d8fcba9e97db016495d06678be
First added on: Feb 08, 2025